Current concepts in laboratory testing to guide antimicrobial therapy

Mayo Clinic Proceedings

Volumn 87, Issue 3, 2012, Pages 290-308

  Jenkins, Stephen G ^a   Schuetz, Audrey N ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAMASE; BETA LACTAMASE AMPC; CARBAPENEMASE; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ETHAMBUTOL; GENTAMICIN; IMIPENEM; ISONIAZID; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; PENICILLIN G; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TOBRAMYCIN; TRIMETHOPRIM SULFATE; VANCOMYCIN;

ACCURACY; ACTINOBACTERIA; AGAR DIFFUSION; AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BROTH DILUTION; CANDIDA ALBICANS; CONFERENCE PAPER; DISK DIFFUSION; ENZYME ASSAY; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FUNGUS ISOLATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INTERMETHOD COMPARISON; KLEBSIELLA PNEUMONIAE; LABORATORY TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; NOCARDIA; NONHUMAN; NUCLEIC ACID HYBRIDIZATION; PREDICTION; PROCESS DEVELOPMENT; PROTEUS MIRABILIS; REAL TIME POLYMERASE CHAIN REACTION; SALMONELLA; SERUM BACTERICIDAL ANTIBODY ASSAY; STREPTOCOCCUS PYOGENES;

EID: 84857964229     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.01.007     Document Type: Conference Paper

References (129)

1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Disease Society of America. Clin Infect Dis. 2009;48(1):1-12.
2. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved standard, 9th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2012. CLSI publication M7-A9.
3. International Organization for Standardization. Susceptibility Testing of Infectious Agents and Evaluation of Performance of Antimicrobial Susceptibility Devices, Part 1: Reference Method for Testing the In Vitro Activity of Antimicrobial Agents against Bacteria Involved in Infectious Diseases. Vol. ISO/DIS 20776-1. Geneva, Switzerland: International Organization for Standardization; 2006.
4. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests. Approved standard, 11th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2012. CLSI publication M02-A11.
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 21st informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2012. CLSI publication M100-S22.
6. Barry AL, Badal RE, Hawkinson RW. Influence of inoculum growth phase on microdilution susceptibility tests. J Clin Microbiol. 1983;18(3):645-651. (Pubitemid 13004213)
7. Metzler CM, DeHaan RM. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis. 1974;130(6):588-594.
8. Clinical and Laboratory Standards Institute. Development of In Vitro Susceptibility Testing Criteria and Quality ControlParameters. Approved guideline, 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. CLSI publication M23-A3.
9. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45(4):493-496.
10. Baker CN, Stocker SA, Culver DH, Thornsberry C. Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol. 1991;29(3):533-538.
11. Huang MB, Baker CN, Banerjee S, Tenover FC. Accuracy of the E Test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejuni, and gram-negative bacteria resistant to antimicrobial agents. J Clin Microbiol. 1992;30(12):3243-3248.
12. Pfaller MA, Jones RN. Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003). Arch Pathol Lab Med. 2006;130(6):767-778. (Pubitemid 43886994)
13. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. Approved guideline, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2010. CLSI publication M45-A2.
14. Goldstein EJ, Citron DM, Merriam CV, Abramson MA. Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surg Infect. 2009;10(2):111-118.
15. Lassmann B, Gustafson DR, Wood CM, Rosenblatt JE. Reemergence of anaerobic bacteremia. Clin Infect Dis. 2007;44(7):895-900. (Pubitemid 46452050)
16. Robert R, Deraignac A, Le MG, Ragot S, Grollier G. Prognostic factors and impact of antibiotherapy in 117 cases of anaerobic bacteremia. Eur J Clin Microbiol Infect Dis. 2008;27(8):674-678.
17. Salonen JH, Eerola E, Meurman O. Clinical significance and outcome of anaerobic bacteremia. Clin Infect Dis. 1998;26(6):1413-1417. (Pubitemid 28270174)
18. Wilson JR, Limaye AP. Risk factors for mortality in patients with anaerobic bacteremia. Eur J Clin Microbiol Infect Dis. 2004;23(4):310-316. (Pubitemid 38669941)
19. Zahar JR, Farhat H, Chacaty E, Meshaka P, Antoun S, Nitenberg G. Incidence and clinical significance of anaerobic bacteremia in cancer patients: a 6-year retrospective study. Clin Microbiol Infect. 2005;11(9):724-729. (Pubitemid 41167338)
20. Baron EJ, Citron DM, Wexler HM. Son of anaerobic susceptibility testing - revisited. Clin Microbiol Newsletter. 1990;12(9):69-70.
21. Dougherty SH. Antimicrobial culture and susceptibility testing has little value for routine management of secondary bacterial peritonitis. Clin Infect Dis. 1997;25(suppl 2):S258-S261.
22. Finegold SM. Perspective on susceptibility testing of anaerobic bacteria. Clin Infect Dis. 1997;25(suppl 2):S251-S253.
23. Rosenblatt JE, Brook I. Clinical relevance of susceptibility testing of anaerobic bacteria. Clin Infect Dis. 1993;16(suppl 4):S446-S448. (Pubitemid 23157971)
24. Wilson SE, Huh J. In defense of routine antimicrobial susceptibility testing of operative site flora in patients with peritonitis. Clin Infect Dis. 1997;25(suppl 2):S254-S257.
25. Golan Y, McDermott LA, Jacobus NV, et al. Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother. 2003;52(2):208-213. (Pubitemid 36986881)
26. Nguyen MH, Yu VL, Morris AJ, et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis. 2000;30(6):870-876. (Pubitemid 32250323)
27. Hecht DW, Osmolski JR, O'Keefe JP. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals. Clin Infect Dis. 1993;16(suppl 4):S357-S360. (Pubitemid 23157947)
28. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of tends in the United States from 1997 to 2004. Antimicrob Agents Chemother. 2007;51(5):1649-1655. (Pubitemid 46744140)
29. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997-2000. Clin Infect Dis. 2002;35(suppl 1):S126-S134.
30. Snydman DR, Jacobus NV, McDermott LA, et al. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother. 1999;43(10):2417-2422. (Pubitemid 29471221)
31. Clinical and Laboratory Standards Institute. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data. Approved guideline, 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2009. CLSI publication M39-A3.
32. Clinical and Laboratory Standards Institute. Acceptable Anaerobe Control Strain Ranges for Minimal Inhibitory Concentration (MIC) Determination by Broth Microdilution and Agar Dilution Testing and Cumulative Antimicrobial Susceptibility Report for Bacteroides fragilis Group Bacteria. Approved standard informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2009. CLSI publication M11-S1.
33. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. Approved standard, 7th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2007. CLSI publication M11-A7.
34. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. Approved standard, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. CLSI publication M24-A2.
35. Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev. 2006;19(2):259-282.
36. Verroken A, Janssens M, Berhin C, et al. Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of Nocardia species. J Clin Microbiol. 2010;48(11):4015-4021.
37. Wallace RJ Jr, Steele LC, Sumter G, Smith JM. Antimicrobial susceptibility patterns of Nocardia asteroides. Antimicrob Agents Chemother. 1988;32(12):1776-1779.
38. Ambaye A, Kohner PC, Wollan PC, Roberts KL, Roberts GD, Cockerill FR III. Comparison of agar dilution, broth microdilution, disk diffusion, E-test, and BACTEC radiometric methods for antimicrobial susceptibility testing of clinical isolates of the Nocardia asteroides complex. J Clin Microbiol. 1997;35(4):857-852.
39. Udhe KB, Pathak S, McCullum I Jr, et al. Antimicrobial-resistant Nocardia isolates, United States, 1995-2004. Clin Infect Dis. 2010;51(12):1445-1448.
40. Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep. 1993;42(RR-7):1-8.
41. Styrt BA, Shinnick TM, Ridderhof JC, Crawford JT, Tenover FC. Turnaround time for mycobacterial cultures. J Clin Microbiol. 1997;35(4):1041-1042.
42. Kent PT, Kubica GP. Public Health Mycobacteriology: A Guide for the Level III Laboratory. Atlanta, GA: Centers for Disease Control and Prevention; 1985.
43. In: Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. Approved standard, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. CLSI publication M24-S2
44. Scarparo C, Ricordi P, Ruggiero G, Piccoli P. Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method. J Clin Microbiol. 2004;42(3):1109-1114. (Pubitemid 38332833)
45. Hoek K, Van Rie A, van Helden PD, Warren RM, Victor TC. Detecting drug-resistant tuberculosis: the importance of rapid testing. Mol Diagn Ther. 2011;15(4):189-194.
46. Griffith DE, Askamit T, Brown-Elliott BA, et al. An official ATS-IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367-416.
47. Hindler J. Antimicrobial susceptibility tests. In: Isenberg HD, ed. Essential Procedures in Clinical Microbiology. Washington, DC: American Society for Microbiology; 1997:105-154.
48. Leitch C, Boonlayangoor S. β-Lactamase tests. In: Isenberg HD, ed. Clinical Microbiology Procedures Handbook. Washington, DC: American Society for Microbiology; 1992:5.3.1-5.3.8.
49. Dyke JW. β-Lactamases of Staphylococcus aureus. In: Hamilton- Miller JM, ed. β-Lactamases. London, England: Academic Press; 1979:291-310.
50. Kaase M, Lenga S, Friedrich S, Szabados F, Sakinc T, Feibelkorn KR. Comparison of phenotypic methods for penicillinase detection in Staphylococcus aureus. Clin Microbiol Infect. 2008;14(6):614-616. (Pubitemid 351639080)
51. Tang YW, Stratton CW. Staphylococcus aureus: an old pathogen with new weapons. Clin Lab Med. 2010;30(1):179-208.
52. Malhotra-Kumar S, Haccuria K, Michiels M, et al. Current trends in rapid diagnostics for methicillin-resistant Staphylococcus aureus and glycopepetide-resistant Enterococcus species. J Clin Microbiol. 2008;46(5):1577-1587. (Pubitemid 351657198)
53. Flayhart D, Hindler JF, Bruckner DA, et al. Multicenter evaluation of BBL CHROMagar MRSA medium for direct detection of methicillin-resistant Staphylococcus aureus from surveillance cultures of the anterior nares. J Clin Microbiol. 2005;43(11):5536-5540. (Pubitemid 41612326)
54. Struelens MJ, Hawkey PM, French GL, Witte W, Tacconelli E. Laboratory tools and strategies for methicillin-resistant Staphylococcus aureus screening, surveillance and typing: state of the art and unmet needs. Clin Microbiol Infect. 2009;15(2):112-119.
55. Marlowe EM, Bankowski MJ. Conventional and molecular methods for the detection of methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2011;49(9):S53-S56.
56. Paule SM, Pasquariello AC, Thomson RB Jr, Kaul KL, Peterson LR. Real-time PCR can rapidly detect methicillin-susceptible and methicillin-resistant Staphylococcus aureus directly from positive blood culture bottles. Am J Clin Pathol. 2005;124(3):404-407. (Pubitemid 41232926)
57. Carey BE, Nicol L. The combined oxacillin resistance and coagulase (CORC) test for rapid identification and prediction of oxacillin resistance in Staphylococcus species directly from blood culture. J Clin Pathol. 2008;61(7):866-868. (Pubitemid 351969735)
58. Swenson JM, Ferraro MJ, Sahm DF, Clark NC, Culver DH, Tenover FC; National Committee for Clinical Laboratory Standards Study Group on Enterococci. Multilaboratory evaluation of screening methods for detection of high-level aminoglycoside resistance in enterococci. J Clin Microbiol. 1995;33(11):3008- 3018.
59. Chen Y, Marshall SA, Winokur PL, et al. Use of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan Dried Overnight Gram-Positive MIC panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci. J Clin Microbiol. 1998;36(10):2996-3001. (Pubitemid 28429427)
60. Chow JW. Aminoglycoside resistance in enterococci. Clin Infect Dis. 2000;31(2):586-589. (Pubitemid 32289595)
61. Watanabe S, Kobayashi N, Quinones D, Nagashima S, Uehara N, Watanabe N. Genetic diversity of enterococci harboring the high-level gentamicin resistance gene aac(6′)-Ieaph(2")-Ia or aph(2")-Ie in a Japanese hospital. Microb Drug Resist. 2009;15(3):185-194.
62. Yean CY, Yin LS, Lalitha P, Ravichandran M. A nanoplex PCR assay for the rapid detection of vancomycin and bifunctional aminoglycoside resistance genes in Enterococcus species. BMC Microbiol. 2007;7:112.
63. Salgado CD. The risk of developing a vancomycin-resistant Enterococcus bloodstream infection for colonized patients. Am J Infect Control. 2008;36(10):S175-S178.
64. Tacconelli E, Cataldo MA. Vancomycin-resistant enterococci (VRE): transmission and control. Int J Antimicrob Agents. 2008;31(2):99-106.
65. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000;13(4):686-707.
66. Courvalin P. Vancomycin resistance in gram positive-cocci. Clin Infect Dis. 2006;42(suppl 1):S25-S34.
67. Gazin M, Lammens C, Goossens H, Malhotra-Kumar S. Evaluation of GeneOhm VanR and Xpert vanA/vanB molecular assays for the rapid detection of vancomycin-resistant enterococci [published online ahead of print June 12, 2011]. Eur J Clin Microbiol Infect Dis. doi 10.1007/s10096-011-1306-y.
68. Stamper PD, Shulder S, Bekalo P, et al. Evaluation of BBL CHROMagar VanRE for detection of vancomycin-resistant enterococci in rectal swab specimens. J Clin Microbiol. 2010;48(11):4294-4297.
69. Shigei J, Tan G, Shiao A, de la Maza LM, Peterson EM. Comparison of two commercially available selective media to screen for vancomycin-resistant enterococci. Am J Clin Pathol. 2002;117(1):152-155. (Pubitemid 34052485)
70. Marner ES, Wolk DM, Carr J, et al. Diagnostic accuracy of the Cepheid GeneXpert vanA/vanB assay ver. 1.0 to detect the vanA and vanB vancomycin resistance genes in Enterococcus from perianal specimens. Diagn Microbiol Infect Dis. 2011;69(4):382-389.
71. Malhotra-Kumar S, Haccuria K Michiels M, et al. Current trends in rapid diagnostics for methicillin-resistant Staphylococcus aureus and glycopeptide-resistant enterococcus species. J Clin Microbiol. 2008;46(5):1577-1587. (Pubitemid 351657198)
72. Bowling JE, Owens AE, McElmeel ML, et al. Detection of inducible clindamycin resistance in beta-hemolytic streptococci by using the CLSI broth microdilution test and erythromycin-clindamycin combinations. J Clin Microbiol. 2010;48(6):2275-2277.
73. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002;34(4):482-492. (Pubitemid 34112269)
74. Richter SS, Heilmann KP, Dohrn CL, et al. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob Agents Chemother. 2011;55(9):4154-4160.
75. Merino Diaz L, Torres Sanchez MJ, Aznar Martin J. Prevalence and mechanisms of erythromycin and clindamycin resistance in clinical isolates of beta-hemolytic streptococci of Lancefield groups A, B, C, and G in Seville, Spain. Clin Microbiol Infect. 2008;14(1):85-87.
76. Ji M, Lee M, Noh S, Kim MN. Evaluation of the performance of the MicroScan Pos Breakpoint Combo Panel Type 28 for susceptibility testing of Staphylococcus aureus: low-range minimum inhibitory concentration of vancomycin, cefoxitin screening, and inducible clindamycin resistance detection. Korean J Lab Med. 2010;30(6):637-646.
77. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis. 2009;15(8):1260-1264.
78. Jorgensen JH, McElmeel ML, Fulcher LC, McGee L, Glennen A. Evaluation of disk approximation and single-well broth tests for detection of inducible clindamycin resistance in Streptococcus pneumoniae. J Clin Microbiol. 2011;49(9):3332-3333.
79. Dubois V, Arpin C, Noury P, Quentin C. Clinical strain of Pseudomonas aeruginosa carrying a blaTEM-21 gene located on a chromosomal interrupted TnA type transposon. Antimicrob Agents Chemother. 2002;46(11):3624-3626. (Pubitemid 35192937)
80. European Committee on Antimicrobial Susceptibility Testing website. www.eucast.org/epert-rules. Accessed October 31, 2011.
81. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev. 2007;20(3):440-458.
82. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase. Antimicrob Agents Chemother. 2007;51(4):1553-1555. (Pubitemid 46586851)
83. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Nineteenth informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2009. CLSI publication M100-S19.
84. Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol. 2007;45(8):2723-2725. (Pubitemid 47295515)
85. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified Hodge and EDTA: disk synergy tests to screen metallo-beta-lactamase producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect. 2001;7(2):88-91. (Pubitemid 34960278)
86. Jacoby GA. AmpC β-lactamases. Clin Microbiol Rev. 2009;22(1):161-182.
87. Philippon A, Arlet G, Jacoby GA. Plasmid-determined Amp-C type β-lactamases. Antimicrob Agents Chemother. 2002;46(1):1-11.
88. Coudron PE, Moland ES, Thomson KS. Occurrence and detection of AmpC β-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol. 2000;38(5):1791-1796. (Pubitemid 30253917)
89. Black JA, Thomson KS, Pitout JDD. Use of β-lactamase inhibitors in disk tests to detect plasmid-mediated AmpC β-lactamases. J Clin Microbiol. 2004;42(5):2203-2206. (Pubitemid 38637842)
90. Nasim K, Elsayed S, Pitout JDD, Conly J, Church DL, Gregson DB. New method for laboratory detection of AmpC β-lactamases in Escherichia coli and Klebsiella pneumoniae. J Clin Microbiol. 2004;42(10)4799-4802. (Pubitemid 39362406)
91. Black JA, Thomson KS, Buynak JD, Pitout JD. Evaluation of β-lactamase inhibitors in disk tests for detection of plasmid-mediated AmpC β-lactamases in well-characterized clinical strains of Klebsiella spp. J Clin Microbiol. 2005;43(8):4168-4171. (Pubitemid 41129716)
92. Yagi T, Wachino J, Kurokawa H, et al. Practical methods using boronic acid compounds for identification of class C β-lactamase- producing Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol. 2005;43(6):2551-2558. (Pubitemid 40827918)
93. Coudron PE. Inhibitor-based methods for detection of plasmid- mediated AmpC β-lactamases in Klebsiella spp. Escherichia coli, and Proteus mirabilis. J Clin Microbiol. 2005;43(8):4163-4167. (Pubitemid 41129715)
94. Tan TY, Ng LSY, He J, Koh TH, Hsu LY. Evaluation of screening methods to detect plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. Antimicrob Agents Chemother. 2009;53(1):146-149.
95. Tenover FC, Emery SL, Spiegel CA, et al. Identification of plasmid-mediated AmpC β-lactamases in Escherichia coli, Klebsiella spp. and Proteus species can potentially improve reporting of cephalosporin susceptibility testing results. J Clin Microbiol. 2009;47(2):294-299.
96. Sculier JP, Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med. 1984;76(3):429-435. (Pubitemid 14159554)
97. Reller RB. The serum bactericidal test. Rev Infect Dis. 1986; 8(5):803-808.
98. DeGirolami PC, Eliopoulos G. Antimicrobial susceptibility tests and their role in therapeutic drug monitoring. Clin Lab Med. 1987;7(3):499-513.
99. Clinical and Laboratory Standards Institute/NCCLS. Methods for Determining Bactericidal Activity of Antimicrobial Agents. Wayne, PA: NCCLS; 1999. NCCLS document M26-A.
100. Denny AE, Peterson LR, Gerding DN, Hall WH. Serious staphylococcal infections with strains tolerant to bactericidal antibiotics. Ann Intern Med. 1979;139(9):1026-1031. (Pubitemid 10115902)
101. Handwerger S, Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Rev Infect Dis. 1985;7(3):368-386.
102. Tuomanen E, Durack DT, Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Antimicrob Agents Chemother. 1986;30(4):521-527. (Pubitemid 16030691)
103. Saiman L. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for.' Paediatr Respir Rev. 2007;8(3):249-255. (Pubitemid 47440663)
104. Bayer AS, Morrison JO. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin- susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1984;26;(2):220-223. (Pubitemid 14050231)
105. Cappelletty DM, Ryback MJ. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996;40(3):677-683. (Pubitemid 26071535)
106. Pankey GA, Ashcraft DS. The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest and time-kill assay. Diagn Microbiol Infect Dis. 2009;63(2):228-232.
107. Clinical and Laboratory Standards Institute/NCCLS. Methodology for the Serum Bactericidal Test. Wayne, PA: NCCLS; 1999. NCCLS document M21-A.
108. Schlichter JG, MacLean H, Milzer A. Effective penicillin therapy in subacute bacterial endocarditis and other chronic infections. Am J Med Sci. 1949;217(6):600-6083.
109. Weinstein MP, Stratton CW, Ackley A, et al. Multicenter collaborative evaluation of a standardized bactericidal test as a prognostic indicator in infective endocarditis. Am J Med. 1985;78(2):262-269. (Pubitemid 15162927)
110. Weinstein MP, Stratton CW, Hawley HB, Ackley A, Reller LB. Multicenter collaborative evaluation of a standardized bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med. 1987;83(2):218-222.
111. Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009:52(3):197-205.
112. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Third informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. CLSI publication M27-S3.
113. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard, 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. CLSI publication M27-A3.
114. Clinical and Laboratory Standards Institute. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts. Approved guideline, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2009. CLSI publication M44-A2.
115. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. Approved standard, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. CLSI publication M38-A2.
116. Clinical and Laboratory Standards Institute. Method for Antifungal Disk Diffusion Susceptibility Testing of Nondermatophyte Filamentous Fungi. Approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2010. CLSI publication M51-A.
117. Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, pharmacodynamics, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis. 2011;70(3):330-343.
118. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A. Wild-type MIC distributions, epidemiological cutoff values and species- specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat. 2010;13(6):180-195.
119. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat. 2011;14(3):164-176.
120. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagn Microbiol Infect Dis. 2011;71(3):252-259.
121. Martos AI, Romero A, González MT, et al. Evaluation of the E-test method for susceptibility testing of Aspergillus spp. and Fusarium spp. to three echinocandins. Med Mycol. 2010;48(6):858-861.
122. Pfaller MA, Chatuverdi V, Diekema DJ, et al. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. J Clin Microbiol. 2008;46(7):2155-2159.
123. Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N, et al. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J Clin Microbiol. 2007;45(6):1811-1820. (Pubitemid 46933912)
124. Peterson JF, Pfaller MA, Diekema DJ, Rinaldi MG, Riebe KM, Ledeboer NA. Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp. J Clin Microbiol. 2011;49(5):1765-1771.
125. Klutts JS, Robinson-Dunn B. A critical appraisal of the role of the clinical microbiology laboratory in diagnosis of invasive fungal infections. J Clin Microbiol. 2011;49(9):S39-S42.
126. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas. Approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. CLSI publication M43-A.
127. Cao B, Zhao CJ, Yin YD, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis. 2010;51(2):189-194.
128. Averbuch D, Hidalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis. 2011;17(6):1079-1082.
129. Jenkins SG, Jerris RC. Critical assessment of issues applicable to development of antimicrobial susceptibility testing breakpoints. J Clin Microbiol. 2011;49(9, suppl):S5-S14.